Riptide Bioscience, Inc.

941 Railroad Avenue
Vallejo
California
94592
United States

Tel: 650-369-4100
Fax: 650-227-2288

Email: info@riptidebio.com

Show jobs for this employer

About Riptide Bioscience, Inc.

Riptide Biosciences, Inc., is a preclinical-stage drug development firm. Our scientific efforts are led by our President, Dr. George Martin, former Scientific Director of the National Institute on Aging, and we are advised by leading researchers including Dr. Don Kennedy, former head of the FDA, and Dr. Frank McCormick, leader of the National Cancer Institute's KRAS initiative.

Riptide’s antimicrobial development program focuses on engineered peptides which are improved analogs to naturally occurring host defense peptides (HDPs).  In research supported by the NIH and the US Defense Department, our drug candidates have shown remarkable efficacy in several key indications, and a reduced likelihood of bacterial resistance.

In addition, Riptide has been actively developing novel peptide-derived therapeutics with potent immunomodulatory activity.  One class of small synthetic peptides, modeled on naturally occurring peptide fragments, has been shown to dramatically downregulate fibrosis in bleomycin-challenge models of pulmonary fibrosis.  In addition, as demonstrated in collaborative research with the National Cancer Institute, Riptide’s drug candidates profoundly alter the tissue microenvironment surrounding solid organ cancers, improving tumor inhibition and survival. 

3 articles about Riptide Bioscience, Inc.